QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results